Paper34818481
New Horizons in the Treatment of Osteosarcoma.
Meltzer PS and 1 other. N Engl J Med, 2021. Cited by 544 papers, by iCite.
Cite this record
ConductScience Library. New Horizons in the Treatment of Osteosarcoma. Papers, record 34818481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34818481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Bone Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Osteosarcoma | Major topic |
| Humans | |
| Neoadjuvant Therapy | |
| Precision Medicine | |
| Prognosis | |
| Survival Rate |
Source PubMed
Cited by413
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 544 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967266 | FBXO17 promotes osteosarcoma progression by regulating glycolysis and macrophage polarization. | J Mol Histol | 2026 | https://conductscience.org/library/papers/42967266 | PubMed |
| 42900185 | Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300. | J Exp Med | 2026 | https://conductscience.org/library/papers/42900185 | PubMed |
| 42876757 | Pathological mechanisms of long non-coding RNA FOXD2-AS1 promoting osteosarcoma mediated by the COI-1/OCN/Runx-2 signaling pathway. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42876757 | PubMed |
| 42864811 | A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42864811 | PubMed |
| 42845418 | Integrated multi-omic analysis of pediatric metastatic osteosarcoma reveals endothelial cell plasticity and lineage infidelity. | bioRxiv | 2026 | https://conductscience.org/library/papers/42845418 | PubMed |
| 42826198 | An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy. | Sci Adv | 2026 | https://conductscience.org/library/papers/42826198 | PubMed |
| 42798652 | Integrative single-cell and bulk transcriptomics uncovers a lipid metabolism-related lncRNA signature alongside the ELFN1-AS1/LYPLA1 axis driving osteosarcoma progression. | Front Immunol | 2026 | https://conductscience.org/library/papers/42798652 | PubMed |
| 42795789 | Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt. | J Clin Med | 2026 | https://conductscience.org/library/papers/42795789 | PubMed |
| 42787737 | Nutritional biomarkers regulating tumor immune microenvironment in osteosarcoma and as predictors of immune checkpoint inhibitor responses. | Front Immunol | 2026 | https://conductscience.org/library/papers/42787737 | PubMed |
| 42779977 | Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma. | bioRxiv | 2026 | https://conductscience.org/library/papers/42779977 | PubMed |
| 42769412 | Rule-derived preoperative inflammatory-lymphocyte recovery phenotype and pathological response in resected osteosarcoma: a retrospective cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42769412 | PubMed |
| 42723688 | Pulmonary metastasectomy and response-adapted preoperative surveillance in resectable metastatic osteosarcoma: a single-center retrospective cohort study with long-term follow-up. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42723688 | PubMed |
| 42662799 | A universal consuming endogenous H2S strategy using bismuth-metal-organic nanocapsule networks for overcoming osteosarcoma cisplatin resistance. | Bioact Mater | 2027 | https://conductscience.org/library/papers/42662799 | PubMed |
| 42662506 | LNP-mediated silencing of oncogenic lncRNA PVT1 enhances chemotherapeutic efficacy in osteosarcoma. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42662506 | PubMed |
| 42652069 | Integrated Bulk and Single-Cell Transcriptomics Reveals the C3-C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652069 | PubMed |
| 42647168 | Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma. | Cell Rep | 2026 | https://conductscience.org/library/papers/42647168 | PubMed |
| 42601728 | Potential protective function and causal association of LEPR in osteosarcoma: An integrated bioinformatics analysis and Mendelian randomization study. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/42601728 | PubMed |
| 42591213 | MiRNA-140-3p affects the proliferation and metastasis of osteosarcoma via the UBE2C/PI3K-Akt axis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42591213 | PubMed |
| 42566622 | The efficacy of whole-course nursing on malignant bone and soft tumors of lower limbs: A randomized study. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/42566622 | PubMed |
| 42565568 | Targeting ABCB6 induces ferroptosis in osteosarcoma cells via HIF1A/GPX4 pathway. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/42565568 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34818481
GET https://conductscience.org/api/papers/v1/34818481/cited_by?page=2